Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan

BACKGROUND: High-dose melphalan is of limited benefit as autologous stem-cell transplantation (ASCT) regimen for relapsed/refractory myeloma. Its poor results in this setting prompted us to study a new high-dose combination of infusional gemcitabine/busulfan/melphalan (Gem/Bu/Mel). METHODS: We condu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Haematol
Autori principali: Nieto, Yago, Valdez, Benigno C, Pingali, Sai R, Bassett, Roland, Delgado, Ruby, Nguyen, John, Shah, Nina, Popat, Uday, Jones, Roy B, Andersson, Borje S, Gulbis, Alison, Ahmed, Sairah, Bashir, Qaiser, Parmar, Simrit, Patel, Krina, Myers, Alan, Rondon, Gabriela, Orlowski, Robert Z, Champlin, Richard, Qazilbash, Muzaffar
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844223/
https://ncbi.nlm.nih.gov/pubmed/28522110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(17)30080-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi